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Summary: We studied the effects of long-term suppressive thyroxine treatment on serum markers of bone collagen
synthesis and degradation in thyroid carcinoma patients, and the relationship of these effects to the serum concentra-
tions of thyrotropin, free thyroxine and free triiodothyronine were investigated.
Thirty-seven thyroid carcinoma patients receiving a stable thyroxine dose, and thirty-five controls participated in a
cross-sectional study. Bone collagen synthesis and degradation were measured by using specific radioimmunoassays
to determine the serum concentrations of carboxyterminal propeptide of type I procollagen, and carboxyterminal
telopeptide region of type I collagen, respectively. Serum thyrotropin, free T4 and free T3 were measured by time-
resolved fluoroimmunoassays (Delfia®). Serum carboxyterminal telopeptide region of type I collagen concentrations
of thyroid carcinoma patients were significantly higher than those of the controls (p = 0.0012). Serum carboxyter-
minal propeptide of type I procollagen concentrations did not differ significantly between the patients and controls
(p = 0.85). Significant associations between age or physical activity, and carboxyterminal propeptide of type I
procollagen or carboxyterminal telopeptide region of type I collagen were found in the controls, but not in the
patients. Thyrotropin, free T4 or free T3 were not significantly associated with carboxyterminal propeptide of type
I procollagen or carboxyterminal telopeptide region of type I collagen in either the control or patient group.
From these results it is concluded that long-term suppressive thyroxine treatment seems to accelerate bone degrada-
tion, but not bone fprmatkm, and therefore carries a risk for osteoporosis. Thyrotropin or free thyroid hormones
were not able to predict the accelerated bone degradation within the patient group. The normal regulation of bone
metabolism is altered during long-tenn high dose thyroxine treatment, äs evidenced by the fact that the effects of
age and physical activity were not seen in patients. Differentiated thyroid cancer is generally diagnosed in young
people, and patients may receive high-dose thyroxine treatment for decades. Problems due to side effects, like
accelerated bone degradation, may arise gradually. This risk should be taken into account in the management of
thyroid carcinoma patients.
Introduction suppression, however, remains uncertain (l). Long-term
suppressive thyroxine treatment may cause side effects
Patients with thyroid carcinoma need postoperative thy-
 such a$ an increased risk of osteoporosis (2, 3). Conven-
roxine Substitution. The optimal degree of thyrotropin
 tional ,methods for studying bone metabolism and osteo-
_ porosis include measurements of bone mineral density.
K These methods are expensive, sometimes laborious, and
utüi» radiation. Biochemica. markers for bone metabo-
donated froin Orion Diagnostica, Turku, Finland. lism have also been used, such äs urinary hydroxypro-
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line, pyridinoline and deoxypyridinoline cross-links.
However, if urinary hydroxyproline is used äs an index,
the subject must receive a special diet. New techniques
have been developed for the measurement of specific
indicators of bone metabolism in a single serum sample.
Type I collagen accounts for 90 percent of the organic
matrix of bone. Carboxyterminal propeptide of type I
procollagen is an indicator of type I collagen synthesis
in the body, and carboxyterminal telopeptide parts of
type I collagen are a corresponding indicator of the de-
gradation of type I collagen. These new serum markers
have made it possible to measure bone metabolism eas-
ily (4, 5).
The aims of the present study were to examine:
1) whether long-term thyroxine treatment for the sup-
pression of thyrotropin secretion has effects on biochem-
ical markers of bone metabolism in thyroid cancer pa-
tients;
2) the value of thyrotropin, free thyroxine, and free triio-
dothyronine in the prediction of the possible alterations
in bone metabolism.
Materials and Methods
Subjects
Thirty-seven patients who had undergone a primary radical Opera-
tion for differentiated papillary or follicular thyroid carcinoma, and
thirty-five controls participated in the study. All patients received
long-term suppressive thyroxine treatment. Subject characteristics
are presented in table 1. The procedures followed were in accor-
dance with the Helsinki Declaration of 1975, äs revised in 1983.
Laboratory methods
Bone collagen synthesis and degradation were determined by
measuring the serum concentrations of carboxyterminal propeptide
of type I procollagen, and carboxyterminal telopeptide region of
type I collagen, respectively (Orion Diagnostica, Finland), using
specific radioirnmunoassays (4, 6). Carboxyterminal propeptide of
type I procollagen is a trimeric, globular protein that is cleaved off
from type I collagen molecules beföre the latter are assembled into
fibers. This cleavage must be complete to ensure correct fibril and
fiber formation. Thus the amount of cärboxyterminal propeptide of
type I procollagen released is directly related to the number of
collagen molecules forrned, and the assay of carboxyterminal pro-
peptide of type I procollagen can be used to quantify type I colla-
gen synthesis in the body. Carboxyterminal telopeptide region of
type l collagen is a cross-linked telopeptide frorri type I collagen
fibres. It i s liberated duririg the degradation of type I collagen, and
the carboxyterminal telopeptide region of type I collagen assay can
be used to quantify type l collagen degfadation in the body. Serum
thyrotropin was measured with a third-generation assay based on
time-resolved fluorescence (Delfia® hTSH Ultra, Wallac, Finland)
with a reference interval of 0.5-4.7 mlU/1 established by our own
laboratory. The functional sensitivity of the thyrotropin method was
0.005 mIU/1 (20% betweenrassay CV) (7). Serum free T4 and free
T3 were also measured with time-resolved fluoroimmunoassays
(Delfia). Reference intervals for free T4 and free T3 were 7.6-19.7
pmol/1 (according to rnanufacturer) and 4.2—7.6 pmol/1 (estab^
lished by our own laboratory).
Physical activity index
Participation in leisure^time physical activity was assessed by
using a questionnaire. The subjects were asked the frequency of
participation in physical activity and the average intensity and du-
ration of exercise. A sum index for physical activity was calculated
from the product of intensity X duration X monthly frequency
(8,9).
Statistics
Serum carboxyterrriinal telopeptide region of type I Collagen values
were long transformed for parametric statistical computations, be*
cause the distribution was skewed. The results of thyrotropin, free
Tab. l Subject characteristics. The values are presented äs mean (SD). Hormone concentrations are presented äs median (ränge).
Males
Controls
(n = 7)
Patients
(n = 9)
Age
(years)
48.8 (8.0)
55.8 (9.2)
Females (premenopausal)
Controls 38.3 (8.5)
(n = 23)
Patients 35.5 (9.8)
(n = 19)
Females (postmenopausal)
Controls 51.4(6.4)
(n = 5)
Patients 52.7 (3.4)
(n = 9)
Duration of Thyroxine
thyroxine dosage
treatment
(months) fag/d) ·
48.2(31) 197(48)
39.6(15) 227(41)
56.4(51) 203(32)
Physical
activity
index
55.4 (57)
39.6 (29)
45.3 (35)
52.0 (34)
50.7 (34)
45.4(40)
Thyrotropin
(mIU/1)
1.4 (0.8 -2.2)
0.019 (<0.005-0.7)
1.8 (0.7 -6.8)
0.013 (<0.005-0.7)
2.2 (1.3 -3.1)
0.009 (<0.005 -0.06)
Eür. J. Clin. Chem.
Free T4
(pmol/1)
13.2(11.6-18.2)
20.9(14.7-25.6)
13.6(10.0-16.4)
26.8(15.4-45.7)
13,8(11.9-14.5)
23.5(16.8-30.0)
• P
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Free T3
(pmol/1)
5.6 (4.7- 7.7)
.4.6(3.1-. 7.7)
5.6(3.9- 7.4)
6.4(3.6-13.3)
5.1 (4.8-6.6)
5.9 (3.4-7.6)
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T4 and free T3 are presented äs medians, and non-parametric analy-
ses (Mann-Whitney U-test) were used in the statistical computa-
tions, bccause the distribution was highly skewed. According to
sex and menopausal Status, the subjects were classified into males,
premenopausal females, and postmenopausal females. Carboxyter-
minal telopeptide region of type I Collagen and carboxyterminal
propeptide of type I procollagen were examined between patients
and controls (group) using an analysis of variance (group, meno-
pausal Status) and covariance (age, physical activity index), No
significant group by menopause interaction was found.
The relations of carboxyterminal telopeptide region of type I colla-
gen and carboxyterminal propeptide of type I procol lagen to thyro-
tropin, free T4, free T3, age and physical activity were examined
using linear regression analyses stratified by patient and control
groups. Analyses were performed using version 6.04 of the Statisti-
cal Analysis System (SAS) scientific Software for microcomputers,
and confidence intervals were calculated using the CIA (Confi-
dence Interval Analysis) Software (10).
age + 92.96; R2 = 41%). Also, age was significantly
,related to bone degradation (log carboxyterminal telo-
peptide region of type I collagen = 1.73 — 0.014 X age;
R2 = 31%) in the controls. In contrast, no significant
associations between age or physical activity, and car-
boxyterminal propeptide of type I procollagen or car-
boxyterminal telopeptide region of type I collagen were
found in the patients. Figure l shows the effect of age
on serum markers of bone formation and degradation in
the patients and the controls. Thyrotropin, free T4 or free
T3 were not significantly associated with carboxytermi-
nal propeptide of type I procollagen or carboxyterminal
telopeptide region of type I collagen within either the
control or patient group in the linear regression analyses.
Results
Table 2 shows serum carboxyterminal propeptide of type
I procollagen and carboxyterminal telopeptide region of
type I collagen concentrations in the controls and pa-
tients. Mean serum carboxyterminal telopeptide region
of type I collagen concentrations in thyroid carcinoma
patients were higher than in controls (p = 0.0012).
Mean serum carboxyterminal propeptide of type I pro-
collagen concentrations did not differ significantly be-
tween patients and controls (p = 0.85). No significant
differences were found between genders and meno-
pausal groups. Age and physical activity were included
äs covariates in the analyses.
In the control group, linear regression analyses revealed
that age and physical activity were significantly related
to bone formation (carboxyterminal propeptide of type I
procollagen = 0.29 X physical activity index —0.82 X
Tab. 2 Serum concentrations of carboxyterminal propeptide of
type I procollagen (PICP), and carboxyterminal telopeptide region
of type I collagen (ICTP) in controls and patients. The values are
presented äs means, and 95% confidence intervals are shown in
parentheses. Mean serum carboxyterrninal telopeptide region of
type I collagen concentrations in thyroid careinoma patients were
higher than in controls (p = 0.0012), when an analysis of variance
(group, menopausal Status) and covariance (age, physical activity
index) was used. Means shown in the täble are non-adjusted.
PICP ( §/1) ICTP
Males
Controls (n = 7)
Patients (n = 9)
114.2 (97.1 to 131)
104.9 (80.4 to 129)
Females (premenopausal)
Controls (n = 23) 109.4 (101.0 to 118)
Patients (n = 19) 104.2 (89.2 to 119)
Females (postmenopausal)
Controls (n = 5) 101.0 (82.6 to 119)
Patients (n = 9) 103.9 (83.2 to 125)
2.5(1.8to3.2)
3. l (2.6 to 3.6)
2.8 (2.4 to 3.2)
3.6 (2.9 to 4.3)
2.6(1.4to3.8)
4.0 (3.2 to 4.8)
Discussion
The present study confirmed the finding that the ratio of
bone resorption to bone formation is altered in states
with high thyroid hormone concentrations. Many studies
have shown that thyrotropin suppression caused by high
doses of thyroid hormones decreases bone mass (11 —
14). Recently, it was also shown that thyroxine treatment
with lower doses, in order to keep thyrotropin in refer-
ence interval, has only minor effect, if any, on bone mass
(15, 16). In these studies, bone mass and metabolism
were studied by measurement of bone mineral density
and biochemical markers of bone formation and resorp-
tion, such äs serum alkaline phosphatase, osteocalcin,
urinary hydroxyproline, and urinary pyridinium cross-
links. The advantage of the new serum bone markers
used in the present study, carboxyterminal propeptide of
type I procollagen and carboxyterminal telopeptide re-
gion of type I collagen, lies in their high specificity for
type I collagen which represents 90% of the organic
bone rhatrix. These radioimmunoassays are easy to per-
form, and both measurements correlate well with bone
mass according to histomorphometric studies (17). Bone
mineral density or content cannot be defmed by any bio-
chemical marker. However, carboxyterminal propeptide
of type I procollagen and carboxyterminal telopeptide
region of type I collagen can be used äs indicators of
bone turaover. Factors affecting the elimination of car-
boxyterminal propeptide of type I procollagen and car-
boxyterminal telopeptide region of type I collagen, e. g.
increased glomerular filtration, were not studied in the
present work.
In the present study, age and physical activity were sig-
nificantly related to a serum marker of bone formation,
and age to a serum marker of bone degradation in the
controls. This is in agreement with previous studies (18).
No such associations were found in the patients. It seems
that bone degradation is accelerated during long-term
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 32, 1994 / No. 11
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Fig. l The effect of age on serum concentrations of carboxyter-
minal propeptide of type I procollagen (la), and carboxyterminal
high dose thyroxine therapy. The normal regulation of
bone metabolism is altered during long^term high dose
thyroxine treatment, since the effects of age and physical
activity were not seen in patients. As patients received
thyroid hormone treatment, obvious differences were
found in thyrotropin and thyroid hormone Status be-
tween the patients and controls. Although bone degrada-
tion seems to be accelerated in the patient group (free
thyroid hormone concentrations were higher and thyro-
tropin concentrations were lower than in the controls),
these hormone concentrations were not able to predict
the level of the serum marker of bone degradation within
the patient group in the present study. The age differ-
ences between the male patients and controls had no
major effect on the results of the present study, äs age
was included äs a covariate in the statistical analyses.
- 10
|
2 8 -
Irt
2 -
10 20 30 40 50 60 70 80 ;,.,
Age [a] !·
telopeptide region of type I collagen (Ib) in controls (D) and pa-
tients (o).
In conclusion, long-term suppressive thyroxine treat-
ment increases a serum marker öf bone degradation in
men, and in premenopäüsal and postmenopausal
women. Differentiäted thyroid cancer is generally diag-
nosed in young people and the patients may receive
high-dose thyroxine treatment for decades. Problems
due to side effects, such äs accelerated bone degrada-
tion, may arise gradually. Serum thyrotropin or free thy-
roid hormone concentrations were not reliable indicators
of the level of the serum marker of bone degradation
within the patient group. Thyroid hormones and thyro-
tropin suppression are essential for thyroid carcinoma
patients. Therefore, longitudinal studies are needed in
order to defme the optimal amount of thyroxine and the
degree of thyrotropin suppression, taking into account
the side effects of the treatment.
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